Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploring natural products library to identify potential inhibitors targeting isoniazid-resistant tuberculosis.

Journal of biomolecular structure & dynamics - 1 Feb 2025

N Madhana Priya, C George Priya Doss, R Magesh

Abstract excerpt

Mycobacterium tuberculosis (MTB) causing tuberculosis (TB) infection is a leading source of illness and death in developing nations, and the emergence of drug-resistant TB remains a significant global threat and a challenge in treating the disease. Mutations in the inhA and katG genes are connected to the principal molecular mechanism of isoniazid (INH) resistance, and continuous treatment of INH for more than a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Biological Products

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Catalase

Share to Drug Discovery

Share to Isoniazid

Share to Molecular Docking Simulation

Share to Oxidoreductases

Share to Small Molecule Libraries

Source

Identifiers

PMID: 37993985
DOI: 10.1080/07391102.2023.2283159

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploring natural products library to identify potential inhibitors targeting isoniazid-resistant tuberculosis.PMID 37993985Read ↗

In silico discovery of potential drug molecules to improve the treatment of isoniazid-resistant Mycobacterium tuberculosis.Semantic proximity Read ↗

Exploration of potential inhibitors for tuberculosis via structure‐based drug design, molecular docking, and molecular dynamics simulation studiesSemantic proximity Read ↗

Computational discovery of potent drugs to improve the treatment of pyrazinamide resistant Mycobacterium tuberculosis mutants.Semantic proximity Read ↗

Screening of Compounds for Anti-tuberculosis Activity, and in vitro and in vivo Evaluation of Potential CandidatesSemantic proximity Read ↗

Direct inhibitors of InhA with efficacy similar or superior to isoniazid in novel drug regimens for tuberculosisSemantic proximity Read ↗

Biological and Biochemical Evaluation of Isatin-Isoniazid Hybrids as Bactericidal Candidates against Mycobacterium tuberculosis.Semantic proximity Read ↗

Pipeline of anti‐Mycobacterium abscessussmall molecules: Repurposable drugs and promising novel chemical entitiesSemantic proximity Read ↗

Molecular investigation of active binding site of isoniazid (INH) and insight into resistance mechanism of S315T-MtKatG in Mycobacterium tuberculosis.Semantic proximity Read ↗

Hybrid Dynamic Pharmacophore Models as Effective Tools to Identify Novel Chemotypes for Anti-tb Inhibitor Design: a Case Study With Mtb-dapbSemantic proximity Read ↗

Investigate Natural Product Indolmycin and the Synthetically Improved Analogue Toward Antimycobacterial Agents.Semantic proximity Read ↗

The design and synthesis of a new lead against tuberculosisSemantic proximity Read ↗

Analysis of interactions of clinical mutants of catalase-peroxidase (KatG) responsible for isoniazid resistance in Mycobacterium tuberculosis with derivatives of isoniazid.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.